NCT01714908: RECEL

Phase II Study of Erlotinib With Concurrent Radiotherapy in Unresectable NSCLC With Activating Mutation of EGFR in Exon 19 or 21

Status unknown Phase 2 Last updated 7 February 2017

What this trial tests

Phase 2 trial testing Erlotinib w Concurrent Radiotherapy in Non-small Cell Lung Cancer in 100 participants. Status unknown.

Timeline

14 December 2012

Primary endpoint
20 August 2018

20 October 2018

Quick facts

Lead sponsor	Jinming Yu
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	14 December 2012
Primary completion	20 August 2018
Estimated completion	20 October 2018
Sites	19 locations across China

Drugs / interventions tested

• Erlotinib w Concurrent Radiotherapy
• etoposide/cis-platin (EP) w Concurrent Radiotherapy

Conditions studied

• Non-small Cell Lung Cancer — all drugs for Non-small Cell Lung Cancer →

Sponsor

Jinming Yu — full company profile →

Who can join

Adults 18 to 75, any sex, with Non-small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Erlotinib with concurrent radiotherapy has superior efficacy and comparable safety profile in unresectable stage III non-small cell lung cancer (NSCLC) patients with activating mutation of epidermal growth factor receptor (EGFR) in exon 19 or 21 versus etoposide plus cis-platin with concurrent radiotherapy.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

1. EGFR targeted therapies and radiation: Optimizing efficacy by appropriate drug scheduling and patient selection.
   Cuneo KC, Nyati MK, Ray D, Lawrence TS. · · 2015 · cited 39× · PMID 26205191 · DOI 10.1016/j.pharmthera.2015.07.002
2. Real-world treatment patterns and clinical outcomes in <i>EGFR</i>-mutant locally advanced lung adenocarcinoma: A multi-center cohort study.
   Bi N, Xu K, Ge H, Chen M, et al · · 2023 · cited 10× · PMID 39036309 · DOI 10.1016/j.jncc.2022.11.003
3. Perspective on treatment for unresectable locally advanced non-small cell lung cancer with oncogene-driven mutation: a narrative review.
   Jiang L, Meng X, Zhao X, Xing L, et al · · 2020 · cited 9× · PMID 33209632 · DOI 10.21037/tlcr-20-722
4. State of the art of radiotherapy.
   Garrido P, M, Olmedo E. · · 2013 · PMID 25806232 · DOI 10.3978/j.issn.2218-6751.2013.03.02